Select a medication above to begin.
Lunsumio (mosunetuzumab-axgb)
mosunetuzumab
Black Box Warnings .
Cytokine Release Syndrome
incl. serious or life-threatening rxn occurred; initiate tx according to step-up dosing schedule to decr. CRS risk; manifestations may incl. fever, chills, hypotension, tachycardia, hypoxia, headache; withhold tx until s/sx resolve or permanently D/C, based on severity; provide supportive care, incl. intensive care for severe or life-threatening CRS, as needed
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = mosunetuzumab-axgb
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, prophylactic antimicrobials, and dosing incl. toxicity-related dose adjustments
follicular lymphoma, relapsed or refractory
- [1 mg IV x1 on day 1, then 2 mg IV x1 on day 8 as part of step-up dosing schedule, then 60 mg IV x1 on day 15 of 21-day cycle for cycle 1, then 60 mg IV x1 on day 1 of 21-cycle for cycle 2, then 30 mg IV x1 on day 1 of 21-day cycle for cycles 3-8]
- Info: for pts who have received at least 2 prior tx; continue x9 additional cycles if complete response not achieved after 8 cycles
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.